Indaptus <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Promising Updates on Decoy20 and Tislelizumab Combination Therapy in Ongoing Clinical Trial
Indaptus Therapeutics Inc. has announced updates on their ongoing INDP-D101 clinical trial involving the Decoy20 combination with the PD-1 inhibitor, tislelizumab. The trial, which is in the clinical stage, aims to explore innovative treatments for cancer and viral infections. The company has completed the monotherapy portion of the trial and initiated a cohort of seven patients for the combination therapy. Among the first three evaluable patients in the combination therapy, one patient exhibited stable disease at the first assessment, while two experienced disease progression. Additionally, a patient in the monotherapy study displayed a partial response with a reduction in liver metastases, although the disease progressed at the next imaging. Indaptus plans to continue dosing additional patients and will present further results in the coming weeks.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indaptus Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-012630), on September 04, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.